The last financing was 3.5 million shares at a purchase price of $3.60 per share. That is actually quite a bit better than the current price of $2.39. Perhaps they just wanted to add to their big war chest so that they secured their financial runway all the way through their anticipated completion of the DCVax-L trial.
News 
Market Data 
Discover 
AI
